Corcept Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Corcept Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About CORT

Corcept Therapeutics, Inc. engages in the business of discovering and developing pharmaceutical products and medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders by modulating the effects of the hormone cortisol. The company was founded by David B. 

CEO
Joseph K. Belanoff
CEOJoseph K. Belanoff
Employees
730
Employees730
Headquarters
Redwood City, California
HeadquartersRedwood City, California
Founded
1998
Founded1998
Employees
730
Employees730

CORT Key Statistics

Market cap
12.64B
Market cap12.64B
Price-Earnings ratio
286.12
Price-Earnings ratio286.12
Dividend yield
Dividend yield
Average volume
809.37K
Average volume809.37K
High today
$121.30
High today$121.30
Low today
$116.73
Low today$116.73
Open price
$119.25
Open price$119.25
Volume
641.87K
Volume641.87K
52 Week high
$126.38
52 Week high$126.38
52 Week low
$28.66
52 Week low$28.66

Stock Snapshot

As of today, Corcept Therapeutics(CORT) shares are valued at $120.39. The company's market cap stands at 12.64B, with a P/E ratio of 286.12.

As of 2026-08-27, Corcept Therapeutics(CORT) stock has fluctuated between $116.73 and $121.30. The current price stands at $120.39, placing the stock +3.1% above today's low and -0.7% off the high.

Corcept Therapeutics(CORT) shares are trading with a volume of 641.87K, against a daily average of 809.37K.

During the past year, Corcept Therapeutics(CORT) stock moved between $28.66 at its lowest and $126.38 at its peak.

During the past year, Corcept Therapeutics(CORT) stock moved between $28.66 at its lowest and $126.38 at its peak.

CORT News

Simply Wall St 7h
Is Corcept’s Earnings Beat And Pipeline Optimism Altering The Investment Case For Corcept Therapeutics?

In recent months, Corcept Therapeutics reported earnings that exceeded analyst expectations, reinforcing interest in its portfolio of treatments targeting sever...

Is Corcept’s Earnings Beat And Pipeline Optimism Altering The Investment Case For Corcept Therapeutics?
Simply Wall St 5d
Have Corcept Therapeutics Insiders Been Selling Stock?

We wouldn't blame Corcept Therapeutics Incorporated ( ) shareholders if they were a little worried about the fact that Gary Robb, the Chief Business Officer & S...

Have Corcept Therapeutics Insiders Been Selling Stock?

Analyst ratings

71%

of 7 ratings
Buy
71.4%
Hold
14.3%
Sell
14.3%

People also own

Based on the portfolios of people who own CORT. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.